CareDx
CDNA
70.00
-1.92
-2.67%
CareDx
US · CDNA
#2371 by market cap
Listed 1970
70.00
-1.92
-2.67%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 44 in the most recent period (2026/Q3).
- Total institutional ownership fell 8.4 percentage points.
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 97.77% -8.42pp
- Institutions
- 328 +44
- As of
- 2026/Q3 vs. prior period
Holder types
Mutual Fund67.48%
Hedge Fund24.17%
Public Company3.32%
Individual/Insider3.29%
Private Company1.22%
Government Pension Fund0.86%
Family Office/Trust0.42%
Insurance Company0.28%
Top holders as of 2026-09-30
BlackRock
9.27% · 4.87M sh
State Street Global Advisors
4.99% · 2.62M sh
Vanguard Capital Management, LLC
4.17% · 2.19M sh
Deerfield Management Company, L.P.
3.80% · 2.00M sh
Baron Capital Group, Inc.
3.69% · 1.94M sh
ARK Investment Management LLC
3.06% · 1.61M sh
Boston Partners Global Investors, Inc.
3.75% · 1.94M sh
Geode Capital Management, LLC
2.82% · 1.48M sh
Gagnon Securities, LLC
3.15% · 1.63M sh
Chevy Chase Trust Company
2.74% · 1.44M sh
Ophir Asset Management Pty Ltd
2.41% · 1.26M sh
Renaissance Technologies Corp.
2.39% · 1.26M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 11 buys · 39 sells
| Name | Role | Stake |
|---|---|---|
| Peter Maag | Former Independent Director | 0.56% |
| Abhishek Jain | Former Chief Financial Officer | 0.48% |
| Michael Goldberg | Independent Chairperson | 0.27% |
| John Hanna | Chief Executive Officer | 0.26% |
| Fred Cohen | Independent Director | 0.25% |
| George Bickerstaff | Independent Director | 0.24% |
| Jeffrey Novack | General Counsel | 0.19% |
| Keith Kennedy | Chief Financial Officer | 0.10% |
| William Hagstrom | Former Independent Director | 0.08% |
| Alexander Johnson | Former President of Patient & Testing Services | 0.08% |
| Jessica Meng | Chief Commercial Officer | 0.08% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-09 | George Bickerstaff | Independent Director | Derivative Exercise and Retained | +15,000 | $14.74 |
| 2026-11-09 | Jeffrey Novack | General Counsel | Automatic Disposition | -4,096 | $80.47–83.33 |
| 2026-11-05 | Jeffrey Novack | General Counsel | Sale to Issuer | -1,505 | $78.56 |
| 2026-11-04 | Keith Kennedy | Chief Financial Officer | Automatic Disposition | -9,539 | $79.49–83.60 |
| 2026-11-04 | Keith Kennedy | Chief Financial Officer | Derivative Exercise and Sale | -52,422 | $29.43–79.49 |
| 2026-11-02 | Fred Cohen | Independent Director | Other Disposition | -25,000 | -- |
| 2026-10-31 | Jeffrey Novack | General Counsel | Sale to Issuer | -2,873 | $85.88 |
| 2026-10-01 | Michael Goldberg | Independent Chairperson | Other Acquisition | +588 | -- |
| 2026-09-30 | Keith Kennedy | Chief Financial Officer | Sale to Issuer | -3,018 | $66.23 |
| 2026-09-30 | John Hanna | Chief Executive Officer | Sale to Issuer | -8,511 | $66.23 |
| 2026-09-30 | Jessica Meng | Chief Commercial Officer | Sale to Issuer | -2,619 | $66.23 |
| 2026-09-30 | Jeffrey Novack | General Counsel | Sale to Issuer | -997 | $66.23 |
| 2026-09-11 | Keith Kennedy | Chief Financial Officer | Sale to Issuer | -8,220 | $52.37 |
| 2026-09-11 | Jessica Meng | Chief Commercial Officer | Sale to Issuer | -6,688 | $52.37 |
| 2026-08-16 | Peter Maag | Former Independent Director | Intent to Sell (Form 144) | -9,122 | $46.38 |
| 2026-08-13 | Peter Maag | Former Independent Director | Intent to Sell (Form 144) | -7,000 | $45.30 |
| 2026-08-12 | Peter Maag | Former Independent Director | Intent to Sell (Form 144) | -7,000 | $47.07 |
| 2026-08-11 | Peter Maag | Former Independent Director | Intent to Sell (Form 144) | -7,000 | $46.89 |
| 2026-08-10 | Peter Maag | Former Independent Director | Intent to Sell (Form 144) | -7,000 | $47.69 |
| 2026-08-09 | Peter Maag | Former Independent Director | Intent to Sell (Form 144) | -6,902 | $47.66 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.
CareDx discussion 0 comments